Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.
about
Diuretics for heart failureDiuretics for heart failureDiuretics for heart failureSustained cardiac diastolic changes elicited by ultrafiltration in patients with moderate congestive heart failure: pathophysiological correlatesCardiorenal syndrome: a cardiologist's perspective of pathophysiologyXamoterol, a beta 1-adrenoceptor partial agonist: review of the clinical efficacy in heart failure.A reappraisal of loop diuretic choice in heart failure patientsThe role of ultrafiltration in patients with decompensated heart failure.Neuroendocrine activity in untreated heart failureDifferences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study.Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure TrialPathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones.Results of clinical trials with diuretics in heart failure.Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group.Tolvaptan: the evidence for its therapeutic value in acute heart failure syndromeRenal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure.Diuretic use in heart failure and outcomes.Therapeutic options for the management of the cardiorenal syndrome.Association between fluid balance and survival in critically ill patientsDecongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failureDrug therapy in chronic heart failure.Aldosterone receptor antagonists: biology and novel therapeutical applications.Use of Loop Diuretics is Associated with Increased Mortality in Patients with Suspected Coronary Artery Disease, but without Systolic Heart Failure or Renal Impairment: An Observational Study Using Propensity Score MatchingRecent advances in natriuretic peptides in congestive heart failure.Diuretic usage in heart failure: a continuing conundrum in 2005.Predictors of emergency department observation unit outcomes.Ultrafiltration for acute decompensated heart failure.Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure.Nesiritide: harmful or harmless?Adaptation of renal function in heart failure.Relationship of Loop Diuretic Dosing and Acute Changes in Renal Function during Hospitalization for Heart Failure.Carvedilol: use in chronic heart failure.Approaches to decongestion in patients with acute decompensated heart failure.The place of ACE inhibitors in the current treatment of chronic heart failure.Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methodsVascular tone in heart failure: the neuroendocrine-therapeutic interfaceNeuroendocrine response to standing and mild exercise in patients with untreated severe congestive heart failure and chronic constrictive pericarditis.Acute Kidney Injury in Pediatric Heart FailureClinical Characteristics and Treatment of Cardiomyopathies in Children.Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.
P2860
Q24185944-F7F0A037-101F-4DDA-941B-3A0F20217190Q24203661-91BF70CE-8FE9-41D2-8C8B-11D25F605D3FQ24244710-F31F48AD-228E-4AB0-91EB-BC91DF16A64AQ24515325-E331787A-FA0A-4BFE-B5A5-2DCDE347DE4DQ27023089-DF52A8FA-12C2-4BDB-BEF6-30A5B64E71C8Q28257885-C35F8B50-5ECA-43A5-AE46-7446DEEFB08AQ28258044-0926E9D4-C8C0-47E8-A49D-CB0F47B09A9AQ30433871-5BDF62B5-70D0-478C-8145-AD0FC4717840Q33611263-58365EB2-294F-4649-A948-C8EA3C8D9A1BQ33611337-814F02D3-3B7E-404F-8882-971702BB5016Q33611888-EC1262F3-F9D4-40A0-B694-747F90FDE267Q33613458-BFFDD33F-24D9-4F50-AC12-0ECCCC87161FQ33614258-B7F93E04-01FD-4AA3-B9BF-B26BFE9FB1C3Q33614319-31BCB513-FCCE-462F-8870-B06020EF9ED8Q33973976-DD646121-1C29-4557-9DB1-75CD459988C9Q34305164-C4F0DC36-6278-481A-99ED-2A6F09301C20Q34357452-463FE16A-CA25-46DC-8517-D4D658D9F3DEQ34442587-06C84EB9-6966-459F-8FEA-63121C93D61EQ34696390-0E4BE504-81CF-425F-B91F-673CC39DC08CQ35071595-C7A00928-6502-47C7-B32D-A1B8CAE3DA94Q35518236-BFE35B96-76BD-4A80-BC76-3F7F8BF3BC7EQ35605655-206D74C1-6709-460C-8B4A-2F7B6ECD0AEBQ35647794-7F2E061C-0A3A-4F98-876D-5F07A4A3CBFBQ35790792-365602ED-4033-4D9E-9A67-9ED909DADB04Q36056333-8F08BA59-B2EA-4360-B429-29832BBF9865Q36248577-50EE4C51-AD68-4183-96D0-58283B85F4B7Q36315167-B02E8A09-8FFA-4C95-B6AC-15C121DCA90FQ36458380-E99F1CF0-D0E8-45A9-BF87-C1D9A359B192Q36603228-6FEB3B20-B0D9-4734-8701-279CDF9E5AA7Q36627825-A3BB0678-CBA2-47E5-B915-F1E2970C2C3EQ36670577-62B09556-18B2-43CC-A950-AD7CBA8DDD40Q36691623-48B5418A-A0CC-48C2-823B-67A2F291C369Q36694354-7EF4D3D2-B666-4B8A-95DC-E284BEC5A2AFQ36722535-844882E7-CE43-4ADB-A947-DAE750BB8314Q36743923-379098A1-E609-4404-8E88-602B2C0DEFA7Q36808117-10F619BA-ECF5-49A7-904A-40E1F3664841Q36833522-49A038BE-B2F9-4226-92C2-11F1DC8F999EQ36886257-4F06EF12-86BE-49DE-9371-6CE5E2CFB98BQ36886275-52448AB0-DDC0-478A-9687-FBA1C717D424Q37170615-0384FF5C-FDFB-42C3-9A2D-A5C1B2A836B3
P2860
Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.
description
1987 nî lūn-bûn
@nan
1987 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
name
Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.
@ast
Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.
@en
Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.
@nl
type
label
Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.
@ast
Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.
@en
Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.
@nl
prefLabel
Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.
@ast
Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.
@en
Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.
@nl
P2093
P2860
P356
P1476
Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.
@en
P2093
Canepa-Anson R
Poole-Wilson P
P2860
P356
10.1136/HRT.57.1.17
P577
1987-01-01T00:00:00Z